Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca increases investment into cancer biomarkers

This article was originally published in Clinica

Executive Summary

AstraZeneca has doubled its investment in Cancer Research UK's biomarker research programme. The project aims to assess whether AstraZeneca's drug candidates kill tumour cells and/or prevent angiogenesis – the growth of new blood vessels. The cash injection will allow the London-based charity to increase its capacity for biomarker discovery and evaluation, from 14,000 biomarker assays per year to up to 30,000 per year. The value of the investment was not disclosed. Meanwhile, Cancer Research UK presented results from a study at the NCRI Cancer Conference in Birmingham, UK, today, which found that levels of circulating tumour cells (CTCs) can be used to measure the effects of current lung cancer drugs. CTC levels were higher in the blood of patients whose cancer had spread, and dropped after chemotherapy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel